"Interleukin-15" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cytokine that stimulates the proliferation of T-LYMPHOCYTES and shares biological activities with IL-2. IL-15 also can induce proliferation and differentiation of B-LYMPHOCYTES.
| Descriptor ID |
D019409
|
| MeSH Number(s) |
D12.644.276.374.465.515 D12.776.467.374.465.515 D23.529.374.465.515
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Interleukin-15".
Below are MeSH descriptors whose meaning is more specific than "Interleukin-15".
This graph shows the total number of publications written about "Interleukin-15" by people in this website by year, and whether "Interleukin-15" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 0 | 2 | 2 |
| 2006 | 0 | 1 | 1 |
| 2007 | 1 | 1 | 2 |
| 2009 | 0 | 1 | 1 |
| 2010 | 1 | 0 | 1 |
| 2012 | 2 | 1 | 3 |
| 2013 | 0 | 2 | 2 |
| 2014 | 1 | 2 | 3 |
| 2015 | 0 | 1 | 1 |
| 2017 | 0 | 2 | 2 |
| 2018 | 1 | 0 | 1 |
| 2019 | 2 | 0 | 2 |
| 2020 | 3 | 0 | 3 |
| 2021 | 0 | 1 | 1 |
| 2023 | 0 | 2 | 2 |
| 2024 | 1 | 0 | 1 |
| 2025 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Interleukin-15" by people in Profiles.
-
IL-2-independent expansion, persistence, and antitumor activity in TIL expressing regulatable membrane-bound IL-15. Mol Ther. 2025 Aug 06; 33(8):3605-3623.
-
Hyperleukocytosis in a neuroblastoma patient after treatment with natural killer T cells expressing a GD2-specific chimeric antigen receptor and IL-15. J Immunother Cancer. 2025 Jan 11; 13(1).
-
Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers. Nature. 2025 Jan; 637(8047):940-946.
-
Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering. Sci Adv. 2023 07 28; 9(30):eadd6997.
-
Molecular mechanisms of snoRNA-IL-15 crosstalk in adipocyte lipolysis and NK cell rejuvenation. Cell Metab. 2023 08 08; 35(8):1457-1473.e13.
-
Natural killer cells and cytotoxic T lymphocytes are required to clear solid tumor in a patient-derived xenograft. JCI Insight. 2021 07 08; 6(13).
-
Modulating TNFa activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia. J Immunother Cancer. 2020 09; 8(2).
-
IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma. Clin Cancer Res. 2020 10 15; 26(20):5520-5533.
-
Glypican-3-Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma. Cancer Immunol Res. 2020 03; 8(3):309-320.
-
NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced In Vivo Persistence and Antitumor Activity against Neuroblastoma. Clin Cancer Res. 2019 12 01; 25(23):7126-7138.